Opella: Strategic Investment by Bpifrance in Sanofi's Consumer Healthcare Division
Deal News | May 05, 2025 | White & Case
Global law firm White & Case LLP has advised Bpifrance in their strategic investment in Opella, the consumer healthcare segment of Sanofi. Sanofi's divestiture involves selling 50 percent of Opella to Clayton, Dubilier & Rice (CD&R), while retaining a 48.2 percent stake in the company. With this move, Bpifrance has acquired a 1.8 percent share in Opella, marking a significant investment toward fostering a formidable independent force in the global consumer healthcare industry. This transaction positions Opella as a leading over-the-counter business with renowned products such as Allegra, Doliprane, and Dulcolax. Additionally, Bpifrance will have representation in Opella's board as part of the transaction build-out. The legal advisement from White & Case was comprehensive, featuring a robust team from various European offices, ensuring seamless strategic execution.
Sectors
- Healthcare
- Investment Banking
- Legal Services
Geography
- France – Bpifrance, the French public investment bank, is a key participant in the transaction.
- United States – CD&R, an American private equity firm, acquired a significant stake in Opella, reflecting cross-border investment interest.
- Global – Opella aims to set its footprint as a global leader in consumer healthcare driven through multinational partnerships.
Industry
- Healthcare – The transaction involves Opella, Sanofi's consumer healthcare business, a prominent player in the over-the-counter market.
- Investment Banking – Bpifrance's strategic investment in Opella indicates significant activity within the investment banking sector as they aim to bolster international opportunities.
- Legal Services – White & Case acted as the legal advisor, playing a crucial role in the investment and divestment transaction process.
Financials
- 1.8 percent – Bpifrance's investment representing its share of Opella's capital.
- 50 percent – Sanofi's divested stake in Opella as part of its strategic transition.
- 48.2 percent – Sanofi's retained stake in Opella post-transaction.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Opella | Target Company | Company | Sanofi's consumer healthcare business involved in the investment and divestment process. |
| Sanofi | Selling Company | Company | Previous major stakeholder in Opella, now retaining a minority stake. |
| Clayton, Dubilier & Rice (CD&R) | Bidding Company | Company | Private equity firm acquiring a controlling stake in Opella. |
| Bpifrance | Investor | Company | French public investment bank acquiring a strategic minority share in Opella and engaging in its board activities. |
| White & Case LLP | Legal Advisor | Company | Global law firm advising Bpifrance on the investment process. |